P2RY12 and myocardial infarction: A large regional health plan entered an OBA with the manufacturer of ticagrelor (Brilinta), a P2Y12 inhibitor, in 2018 and the outcome of interest was recurrent myocardial infarction (MI) after an acute coronary syndrome (ACS) discharge.